| Regulatory status | BUNDLE |
|---|---|
| Mechanism | Amylin analogue + GLP-1 (two-vial bundle) |
| Form | Two lyophilized vials · 5mg + 5mg, 10mg + 10mg |
| CAS | Investigational (bundle of two) |
| Purity docs | Batch-matched COA available on request — ask us. |
| Ships from | Ontario, Canada |
| Intended use | Laboratory research only. Not for human consumption. |
This bundle pairs cagrilintide, the long-acting amylin analogue, with semaglutide, the reference GLP-1 — two distinct satiety pathways in a single order. In the phase 3 REDEFINE-1 trial, the combination (cagrilintide 2.4 mg + semaglutide 2.4 mg weekly, administered as a fixed-dose combination) produced 22.7% mean weight loss at 68 weeks. Each bundle ships as two separate lyophilized vials — one cagrilintide and one semaglutide at the selected strengths, never combined or premixed.
Lyophilized vials: keep sealed, dry, and away from light and heat. Refrigeration at 2–8°C is the best default; −20°C for long-term storage. After reconstitution: refrigerate at 2–8°C and use promptly — no beyond-use date is validated.
The amylin + GLP-1 stack, bundled. One cagrilintide vial + one semaglutide vial.
New here? Read the beginner's guide →
$15 flat shipping Canada-wide · free over $200
The active ingredient in Ozempic and Wegovy — the original once-weekly weight-loss medicine.
GLP-1 receptor agonist
The active ingredient in Mounjaro and Zepbound — the newer, stronger once-weekly weight-loss medicine.
Dual GIP / GLP-1 receptor agonist
A once-weekly weight-loss medicine already approved in China — still experimental in Canada and the US.
Dual GLP-1 / glucagon receptor agonist
